# MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis

> **NCT00495339** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 100 (estimated)

## Conditions studied

- Tuberculosis, Pulmonary

## Interventions

- **DRUG:** Levofloxacin

## Key facts

- **NCT ID:** NCT00495339
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2008-04
- **Final completion:** —
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2009-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00495339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00495339, "MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00495339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*